Japan · Delayed Price · Currency is JPY Sawai Group Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profits grew year-over-year, driven by higher sales prices and lifted shipment restrictions, while one-time gains from asset sales boosted net income. FY 2025 guidance anticipates continued revenue and profit growth, despite drug price pressures and rising costs.
-
Revenue and profits grew year-over-year, aided by a U.S. affiliate share sale and land sale proceeds. The outlook targets further profit growth via new products and increased production, with a 4% full-year revenue increase forecast.
-
Revenue grew 6.7% year-on-year, driven by new and existing products, while operating profit surged due to the absence of litigation costs. FY 2026 forecasts anticipate continued growth in revenue and profit, supported by new product launches and expanded production capacity.
-
Revenue rose 12.5% year-over-year, but operating profit fell 27.4% due to a major patent settlement. Core operating profit increased 9.5%, and full year guidance was revised as production volume lags initial targets.
Fiscal Year 2024
-
The new medium-term plan targets over 25% domestic market share and 25 billion tablet production by 2030, with a focus on governance, capital efficiency, and sustainability. Investments will prioritize R&D, production, and shareholder returns, aiming for JPY 220 billion revenue by FY 2027.